Anupam Rasayan India Q2 EBITDA Rises 41% as Bliss Deal Closes

Anupam Rasayan India Limited reported Q2 FY27 EBITDA of INR 202 crore, up 41% year-on-year, while completing the acquisition of Bliss GVS Pharma Limited during the quarter. Total income reached INR 821 crore, and the company said the acquisition strengthens its plan to build an integrated global pharmaceutical platform.

What did Anupam Rasayan report for Q2 FY27?

Anupam Rasayan reported consolidated total income of INR 821 crore for Q2 FY27, compared with INR 739 crore in the corresponding quarter of the previous year, representing 11% year-on-year growth. EBITDA rose to INR 202 crore from INR 144 crore, a 41% increase over Q2 FY26.

The EBITDA margin was close to 25%, compared with 19% in the year-earlier quarter. The margin expansion was notable because EBITDA increased faster than total income during the period. The company did not provide a Q2 profit-after-tax figure in the supplied earnings-call material.

Management said the first half of FY27 included progress across strategic priorities, including expansion into new end markets and a stronger pharmaceuticals and performance materials business. The company also said its H1 FY27 total income rose 21% year-on-year and EBITDA increased 38%, with improved margins.

Why is the Bliss GVS Pharma acquisition important?

The Bliss GVS Pharma Limited acquisition is important because Anupam Rasayan said it marks a milestone in its effort to create an integrated global pharmaceutical platform. Management referred to the transaction as part of its broader strategy to deepen its pharmaceuticals and performance materials presence.

The company confirmed that the acquisition was completed during Q2 FY27. The supplied material does not state the transaction value, financing structure, expected synergies, or a timetable for integration. It also does not provide a breakdown of the acquired business's revenue or profitability.

Questions during the earnings call focused on Bliss's portfolio of 62 molecules, including more than 48 in regulated markets. Investors also sought information on how many molecules were filed, approved, or commercially launched, as well as possible seasonality in the business. The provided extract records these questions but does not include management's detailed answers.

For investors, the acquisition changes the company's operating context by adding a finished-pharmaceutical dimension to a business previously discussed around specialty chemicals, pharmaceuticals and performance materials. The financial contribution from Bliss cannot yet be assessed from the disclosed Q2 figures alone because the supplied information does not separate organic growth from acquisition-related performance.

How does Q2 FY27 compare with Anupam Rasayan's recent performance?

Anupam Rasayan's Q2 result follows a strong FY26, when revenue rose 65% to INR 2,384 crore and operating cash flow was INR 334 crore. The Q2 FY27 total-income growth rate of 11% was lower than the FY26 revenue growth rate, while EBITDA growth of 41% and the higher margin showed improved operating profitability in the quarter.

The company had reported Q1 FY27 consolidated total income of INR 668 crore, up 36% year-on-year. Q1 EBITDA was INR 175 crore, up 35% year-on-year, with a 26% margin. Q2 total income of INR 821 crore was therefore INR 153 crore higher than Q1, while Q2 EBITDA was INR 27 crore above the preceding quarter.

The comparison also shows that margins remained above the 19% reported in Q2 FY26. Q1 FY27's 26% margin and Q2 FY27's margin of close to 25% indicate that the company has maintained a higher profitability level through the first half than in the comparable quarter last year.

What guidance and operating factors should investors monitor?

Anupam Rasayan has guided for consolidated H2 FY27 revenue of INR 2,400 crore to INR 2,500 crore. It has also maintained full-year consolidated EBITDA margin guidance of 22% to 24%. These targets place continued focus on execution in the second half, particularly after the Bliss acquisition.

Management's stated growth plans include new-product ramps, the Jayhawk initiative and the Bliss acquisition. The supplied material does not provide revenue targets for individual projects or segments. As a result, investors cannot determine the expected contribution of each initiative from the available disclosures.

Anupam Rasayan has also reported an INR 17,496 crore order book in the Q2 FY27 highlights. The extract does not provide the delivery period, customer concentration, conversion schedule, or segment-wise composition of this order book. Those details would be relevant for assessing the visibility of future revenue.

The key reported market implication is therefore operational rather than a stated share-price reaction. Higher EBITDA and a margin near 25% indicate improved profitability in Q2, while the Bliss acquisition adds a new integration task. The company has set a broad H2 revenue range and full-year margin range against which future quarterly disclosures can be measured.

Conclusion

Anupam Rasayan delivered Q2 FY27 total income of INR 821 crore and EBITDA of INR 202 crore, with EBITDA growing 41% year-on-year and margin rising to close to 25%. The completed Bliss GVS Pharma acquisition is the main strategic development alongside the quarterly financial performance, expanding the company's stated pharmaceutical-platform ambitions.

The next disclosures should clarify H2 execution against the INR 2,400 crore to INR 2,500 crore consolidated revenue guidance and the 22% to 24% full-year EBITDA margin guidance. Investors will also watch for additional information on Bliss integration, the 62-molecule portfolio, Jayhawk, new-product ramps and the INR 17,496 crore order book.